Loading the records…
Loading the records…
The ASAP Act (HR6130) mandates Medicare coverage for FDA-cleared blood-based dementia screening tests starting Jan 1, 2028. Labcorp ($LH) and Quest Diagnostics ($DGX) are the two largest independent lab operators with existing FDA-cleared blood-based dementia tests, making them primary beneficiaries of this new mandatory benefit category. The bill is in early legislative stages (referred to committee) with companion bill S3267 in the Senate, but the bipartisan sponsorship and 82 cosponsors indicate strong momentum for a mid-2027 passage timeline.
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Both $LH and $DGX have declined over the past 30 days (LH: -3.62% to $257.16; DGX: -2.55% to $191). This is NOT driven by dementia policy news; it reflects general market weakness in the healthcare services sector. The ASAP Act is a positive fundamental catalyst that is not yet priced into these stocks. As the bill progresses through committee and toward passage, the market should begin to price in the incremental revenue from mandatory Medicare coverage. Investors should view current price levels as attractive entry points given the de-risked regulatory pathway (FDA-cleared tests already exist) and the certainty of the January 1, 2028 effective date if passed.
The ASAP Act (HR6130), introduced November 19, 2025 by Rep. Buchanan (R-FL) with 82 cosponsors, amends the Social Security Act to mandate Medicare coverage for blood-based Alzheimer's disease and related dementias screening tests beginning January 1, 2028. The bill explicitly defines these tests as FDA-cleared or approved genomic sequencing blood tests or equivalent blood-based tests. This is not an authorization bill with a spending ceiling — it mandates coverage under existing Medicare Part B, meaning CMS must establish a reimbursement rate (likely under the Clinical Laboratory Fee Schedule) once the bill becomes law.
The money trail is structural: Medicare covers approximately 60 million Americans aged 65+. Blood-based dementia screening is currently a cash-pay or limited private-pay market. Mandatory Medicare coverage would make these tests available without patient out-of-pocket costs (after deductible), dramatically expanding the addressable patient population. The bill does not authorize a specific dollar amount; instead, it creates a new mandatory spending category within Medicare Part B. Estimated annual Medicare spending could range from $1B to $3B depending on utilization rates and the final CMS payment rate.
Structural winners are Labcorp ($LH) and Quest Diagnostics ($DGX). Both have existing FDA-cleared blood-based dementia tests on the market. Labcorp's test (amyloid tau panel with NFL) and Quest's AD-Detect both target the exact population and test type described in the bill. Smaller diagnostics players ($QDEL, $RVTY) are also in the blood diagnostics space — QuidelOrtho has a cardiac/neurology assay portfolio, and Revvity operates in the applied genomics space — but neither has a directly comparable FDA-cleared blood-based dementia screening test, making their benefit less direct. Their recent 30-day price declines (-29.7% for QDEL, -5.27% for RVTY) reflect broader sector weakness, not dementia-specific headwinds.
The legislative timeline: the bill is in early stages, referred to Energy & Commerce and Ways & Means in the House. Companion bill S3267 was introduced in the Senate. With 82 cosponsors and bipartisan sponsorship, the bill has strong early support, but must pass both chambers and be signed into law before the January 1, 2028 effective date. The most likely passage window is late 2026 or mid-2027. Investors should monitor committee hearings and markups as key catalysts.
Cross-referenced against federal contracts, SEC insider filings & congressional trade disclosures
Multiple independent sources confirm this signal’s market thesis
Matched on shared policy language across AI analyses, with ticker & timing weight
To amend title XXVII of the Public Health Service Act and title XIX of the Social Security Act to require coverage of Alzheimer's biomarker testing under group health plans, group and individual health insurance coverage, and the Medicaid program.
Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act
Stem Cell Therapeutic and Research Reauthorization Act of 2025
Executive orders & memoranda affecting the same sectors or companies
This executive order establishes a Women's Health Division within the NIH to coordinate and accelerate research on understudied women's health conditions, and creates a White House Women's Health Task Force to drive policy reforms and translation of research into clinical practice across federal agencies. It directs specific agencies to prioritize research, data collection, and translation into prevention, diagnosis, and treatment, with a focus on all life stages from infancy through aging.
This executive order directs the Secretaries of State, Labor, and Homeland Security to coordinate with Commerce, Education, and the SBA when processing H-1B petitions, and requires them to consider whether the employer has engaged in layoffs of similarly situated U.S. workers within the past year. It also orders the Labor Department to review past labor condition applications for potential enforcement actions against sponsoring employers, effectively tightening scrutiny on H-1B usage, especially by outsourcing firms.
This proclamation orders the Secretaries of War and Veterans Affairs to mandate rapid, ongoing digital sharing of military personnel and medical records, deploy AI-powered tools for benefits applications, and update existing IT contracts for interoperability. It also requires the Transition Assistance Program to connect separating service members to specific jobs or training programs before discharge.
Free — no credit card
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →